O	0	8	Allergic	Allergic	JJ	B-NP
B-Organ	9	18	pulmonary	pulmonary	JJ	I-NP
O	19	31	inflammation	inflammation	NN	I-NP
O	32	40	promotes	promote	VBZ	B-VP
O	41	44	the	the	DT	B-NP
O	45	56	recruitment	recruitment	NN	I-NP
O	57	59	of	of	IN	B-PP
O	60	71	circulating	circulate	VBG	B-VP
B-Cell	72	77	tumor	tumor	NN	B-NP
I-Cell	78	83	cells	cell	NNS	I-NP
O	84	86	to	to	TO	B-PP
O	87	90	the	the	DT	B-NP
B-Organ	91	95	lung	lung	NN	I-NP
O	95	96	.	.	.	O

O	98	106	Allergen	Allergen	NN	B-NP
O	106	107	-	-	HYPH	O
O	107	114	induced	induce	VBN	B-NP
B-Anatomical_system	115	126	respiratory	respiratory	JJ	I-NP
O	127	139	inflammation	inflammation	NN	I-NP
O	140	151	facilitates	facilitate	NNS	I-NP
O	152	155	and	and	CC	O
O	155	156	/	/	SYM	B-NP
O	156	158	or	or	CC	O
O	159	166	elicits	elicit	VBZ	B-VP
O	167	170	the	the	DT	B-NP
O	171	184	extravasation	extravasation	NN	I-NP
O	185	187	of	of	IN	B-PP
B-Cell	188	203	proinflammatory	proinflammatory	JJ	B-NP
I-Cell	204	214	leukocytes	leukocyte	NNS	I-NP
O	215	217	by	by	IN	B-PP
O	218	222	well	well	RB	B-NP
O	222	223	-	-	HYPH	I-NP
O	223	233	understood	understand	VBN	I-NP
O	234	244	mechanisms	mechanism	NNS	I-NP
O	245	249	that	that	WDT	B-NP
O	250	257	mediate	mediate	VBP	B-VP
O	258	261	the	the	DT	B-NP
O	262	270	movement	movement	NN	I-NP
O	271	273	of	of	IN	B-PP
O	274	282	multiple	multiple	JJ	B-NP
B-Cell	283	287	cell	cell	NN	I-NP
O	288	293	types	type	NNS	I-NP
O	293	294	.	.	.	O

O	295	298	The	The	DT	B-NP
O	299	310	nonspecific	nonspecific	JJ	I-NP
O	311	320	character	character	NN	I-NP
O	321	323	of	of	IN	B-PP
O	324	329	these	these	DT	B-NP
O	330	338	pathways	pathway	NNS	I-NP
O	339	342	led	lead	VBD	B-VP
O	343	345	us	us	PRP	B-NP
O	346	348	to	to	TO	B-VP
O	349	360	hypothesize	hypothesize	VB	I-VP
O	361	365	that	that	IN	B-SBAR
O	366	377	circulating	circulate	VBG	B-VP
B-Cell	378	384	cancer	cancer	NN	B-NP
I-Cell	385	390	cells	cell	NNS	I-NP
O	391	394	use	use	VBP	B-VP
O	395	402	similar	similar	JJ	B-NP
O	403	413	mechanisms	mechanism	NNS	I-NP
O	413	414	,	,	,	O
O	415	424	promoting	promote	VBG	B-VP
B-Cancer	425	434	secondary	secondary	JJ	B-NP
I-Cancer	435	440	tumor	tumor	NN	I-NP
O	441	450	formation	formation	NN	I-NP
O	451	453	at	at	IN	B-PP
B-Multi-tissue_structure	454	460	distal	distal	JJ	B-NP
I-Multi-tissue_structure	461	466	sites	site	NNS	I-NP
O	466	467	.	.	.	O

O	468	470	To	To	TO	B-VP
O	471	475	test	test	VB	I-VP
O	476	480	this	this	DT	B-NP
O	481	491	hypothesis	hypothesis	NN	I-NP
O	491	492	,	,	,	O
O	493	496	the	the	DT	B-NP
O	497	506	frequency	frequency	NN	I-NP
O	507	509	of	of	IN	B-PP
O	510	520	metastasis	metastasis	NN	B-NP
O	521	523	to	to	TO	B-PP
O	524	527	the	the	DT	B-NP
B-Organ	528	532	lung	lung	NN	I-NP
O	533	535	as	as	IN	B-PP
O	536	537	a	a	DT	B-NP
O	538	546	function	function	NN	I-NP
O	547	549	of	of	IN	B-PP
O	550	558	allergic	allergic	JJ	B-NP
B-Organ	559	568	pulmonary	pulmonary	JJ	I-NP
O	569	581	inflammation	inflammation	NN	I-NP
O	582	585	was	be	VBD	B-VP
O	586	594	assessed	assess	VBN	I-VP
O	595	604	following	follow	VBG	B-PP
O	605	608	the	the	DT	B-NP
B-Immaterial_anatomical_entity	609	610	i	i	NN	I-NP
I-Immaterial_anatomical_entity	610	611	.	.	.	I-NP
I-Immaterial_anatomical_entity	611	612	v	v	NN	I-NP
I-Immaterial_anatomical_entity	612	613	.	.	.	I-NP
O	614	623	injection	injection	NN	I-NP
O	624	626	of	of	IN	B-PP
B-Cell	627	630	B16	B16	NN	B-NP
I-Cell	630	631	-	-	HYPH	B-NP
I-Cell	631	634	F10	F10	NN	I-NP
I-Cell	635	643	melanoma	melanoma	NN	I-NP
I-Cell	644	649	cells	cell	NNS	I-NP
O	650	652	in	in	IN	B-PP
O	653	657	mice	mouse	NNS	B-NP
O	657	658	.	.	.	O

O	659	664	These	These	DT	B-NP
O	665	672	studies	study	NNS	I-NP
O	673	679	showed	show	VBD	B-VP
O	680	684	that	that	IN	B-SBAR
O	685	693	allergen	allergen	NN	B-NP
O	693	694	-	-	HYPH	B-NP
O	694	701	induced	induce	VBN	I-NP
B-Organ	702	711	pulmonary	pulmonary	JJ	I-NP
O	712	724	inflammation	inflammation	NN	I-NP
O	725	733	resulted	result	VBD	B-VP
O	734	736	in	in	IN	B-PP
O	737	738	a	a	DT	B-NP
O	739	740	>	>	SYM	I-NP
O	740	741	3	3	CD	I-NP
O	741	742	-	-	HYPH	I-NP
O	742	746	fold	fold	JJ	I-NP
O	747	755	increase	increase	NN	I-NP
O	756	758	in	in	IN	B-PP
B-Cancer	759	763	lung	lung	NN	B-NP
I-Cancer	764	774	metastases	metastasis	NNS	I-NP
O	774	775	.	.	.	O

O	776	780	This	This	DT	B-NP
O	781	789	increase	increase	NN	I-NP
O	790	793	was	be	VBD	B-VP
O	794	803	dependent	dependent	JJ	B-ADJP
O	804	806	on	on	IN	B-PP
B-Cell	807	810	CD4	CD4	NN	B-NP
I-Cell	810	811	(	(	(	O
I-Cell	811	812	+	+	SYM	O
I-Cell	812	813	)	)	)	O
I-Cell	814	815	T	T	NN	B-NP
I-Cell	815	816	-	-	HYPH	B-NP
I-Cell	816	820	cell	cell	NN	I-NP
O	821	831	activities	activity	NNS	I-NP
O	831	832	;	;	:	O
O	833	840	however	however	RB	B-ADVP
O	840	841	,	,	,	O
O	842	844	it	it	PRP	B-NP
O	845	853	occurred	occur	VBD	B-VP
O	854	865	independent	independent	JJ	B-ADJP
O	866	868	of	of	IN	B-PP
O	869	872	the	the	DT	B-NP
O	873	880	induced	induce	VBN	I-NP
O	881	893	eosinophilia	eosinophilia	NN	I-NP
O	894	904	associated	associate	VBN	B-VP
O	905	909	with	with	IN	B-PP
O	910	918	allergen	allergen	NN	B-NP
O	919	930	provocation	provocation	NN	I-NP
O	930	931	.	.	.	O

O	932	946	Interventional	Interventional	JJ	B-NP
O	947	957	strategies	strategy	NNS	I-NP
O	958	964	showed	show	VBD	B-VP
O	965	969	that	that	IN	B-SBAR
O	970	978	existing	exist	VBG	B-NP
O	979	990	therapeutic	therapeutic	JJ	I-NP
O	991	1001	modalities	modality	NNS	I-NP
O	1002	1005	for	for	IN	B-PP
O	1006	1012	asthma	asthma	NN	B-NP
O	1012	1013	,	,	,	O
O	1014	1018	such	such	JJ	B-PP
O	1019	1021	as	as	IN	I-PP
O	1022	1029	inhaled	inhale	VBN	B-NP
O	1030	1045	corticosteroids	corticosteroid	NNS	I-NP
O	1045	1046	,	,	,	O
O	1047	1051	were	be	VBD	B-VP
O	1052	1062	sufficient	sufficient	JJ	B-ADJP
O	1063	1065	to	to	TO	B-VP
O	1066	1071	block	block	VB	I-VP
O	1072	1075	the	the	DT	B-NP
O	1076	1084	enhanced	enhance	VBN	I-NP
B-Organ	1085	1094	pulmonary	pulmonary	JJ	I-NP
O	1095	1106	recruitment	recruitment	NN	I-NP
O	1107	1109	of	of	IN	B-PP
B-Cell	1110	1116	cancer	cancer	NN	B-NP
I-Cell	1117	1122	cells	cell	NNS	I-NP
O	1123	1127	from	from	IN	B-PP
O	1128	1139	circulation	circulation	NN	B-NP
O	1139	1140	.	.	.	O

O	1141	1151	Additional	Additional	JJ	B-NP
O	1152	1163	mechanistic	mechanistic	JJ	I-NP
O	1164	1171	studies	study	NNS	I-NP
O	1172	1179	further	further	RB	B-ADVP
O	1180	1189	suggested	suggest	VBD	B-VP
O	1190	1194	that	that	IN	B-SBAR
O	1195	1198	the	the	DT	B-NP
O	1199	1206	ability	ability	NN	I-NP
O	1207	1209	of	of	IN	B-PP
O	1210	1221	circulating	circulate	VBG	B-VP
B-Cell	1222	1228	cancer	cancer	NN	B-NP
I-Cell	1229	1234	cells	cell	NNS	I-NP
O	1235	1237	to	to	TO	B-VP
O	1238	1249	extravasate	extravasate	VB	I-VP
O	1250	1252	to	to	TO	B-PP
O	1253	1264	surrounding	surround	VBG	B-VP
B-Tissue	1265	1269	lung	lung	NN	B-NP
I-Tissue	1270	1277	tissues	tissue	NNS	I-NP
O	1278	1281	was	be	VBD	B-VP
O	1282	1288	linked	link	VBN	I-VP
O	1289	1291	to	to	TO	B-PP
O	1292	1295	the	the	DT	B-NP
O	1296	1306	activation	activation	NN	I-NP
O	1307	1309	of	of	IN	B-PP
O	1310	1313	the	the	DT	B-NP
B-Tissue	1314	1322	vascular	vascular	JJ	I-NP
I-Tissue	1323	1334	endothelium	endothelium	NN	I-NP
O	1335	1338	via	via	IN	B-PP
O	1339	1342	one	one	CD	B-NP
O	1343	1345	or	or	CC	I-NP
O	1346	1350	more	more	JJR	I-NP
O	1351	1357	Galpha	Galpha	NN	I-NP
O	1357	1358	(	(	(	O
O	1358	1359	i	i	NN	B-NP
O	1359	1360	)	)	)	O
O	1360	1361	-	-	HYPH	B-NP
O	1361	1368	coupled	couple	VBN	I-NP
O	1369	1378	receptors	receptor	NNS	I-NP
O	1378	1379	.	.	.	O

O	1380	1393	Interestingly	Interestingly	RB	B-ADVP
O	1393	1394	,	,	,	O
O	1395	1396	a	a	DT	B-NP
O	1397	1403	survey	survey	NN	I-NP
O	1404	1406	of	of	IN	B-PP
O	1407	1408	a	a	DT	B-NP
O	1409	1417	clinical	clinical	JJ	I-NP
B-Cancer	1418	1424	breast	breast	NN	I-NP
I-Cancer	1425	1431	cancer	cancer	NN	I-NP
O	1432	1440	surgical	surgical	JJ	I-NP
O	1441	1449	database	database	NN	I-NP
O	1450	1456	showed	show	VBD	B-VP
O	1457	1461	that	that	IN	B-SBAR
O	1462	1465	the	the	DT	B-NP
O	1466	1475	incidence	incidence	NN	I-NP
O	1476	1478	of	of	IN	B-PP
O	1479	1485	asthma	asthma	NN	B-NP
O	1486	1489	was	be	VBD	B-VP
O	1490	1496	higher	high	JJR	B-ADJP
O	1497	1502	among	among	IN	B-PP
O	1503	1511	patients	patient	NNS	B-NP
O	1512	1516	with	with	IN	B-PP
B-Cancer	1517	1521	lung	lung	NN	B-NP
I-Cancer	1522	1532	metastases	metastasis	NNS	I-NP
O	1532	1533	.	.	.	O

O	1534	1538	Thus	Thus	RB	B-ADVP
O	1538	1539	,	,	,	O
O	1540	1543	our	our	PRP$	B-NP
O	1544	1548	data	datum	NNS	I-NP
O	1549	1553	show	show	VBP	B-VP
O	1554	1558	that	that	IN	B-SBAR
O	1559	1567	allergic	allergic	JJ	B-NP
B-Anatomical_system	1568	1579	respiratory	respiratory	JJ	I-NP
O	1580	1592	inflammation	inflammation	NN	I-NP
O	1593	1596	may	may	MD	B-VP
O	1597	1606	represent	represent	VB	I-VP
O	1607	1608	a	a	DT	B-NP
O	1609	1613	risk	risk	NN	I-NP
O	1614	1620	factor	factor	NN	I-NP
O	1621	1624	for	for	IN	B-PP
O	1625	1628	the	the	DT	B-NP
O	1629	1640	development	development	NN	I-NP
O	1641	1643	of	of	IN	B-PP
B-Cancer	1644	1648	lung	lung	NN	B-NP
I-Cancer	1649	1659	metastases	metastasis	NNS	I-NP
O	1660	1663	and	and	CC	O
O	1664	1671	suggest	suggest	VBP	B-VP
O	1672	1676	that	that	IN	B-SBAR
O	1677	1689	amelioration	amelioration	NN	B-NP
O	1690	1692	of	of	IN	B-PP
O	1693	1696	the	the	DT	B-NP
B-Organ	1697	1706	pulmonary	pulmonary	JJ	I-NP
O	1707	1719	inflammation	inflammation	NN	I-NP
O	1720	1730	associated	associate	VBN	B-VP
O	1731	1735	with	with	IN	B-PP
O	1736	1742	asthma	asthma	NN	B-NP
O	1743	1747	will	will	MD	B-VP
O	1748	1752	have	have	VB	I-VP
O	1753	1754	a	a	DT	B-NP
O	1755	1761	direct	direct	JJ	I-NP
O	1762	1765	and	and	CC	I-NP
O	1766	1775	immediate	immediate	JJ	I-NP
O	1776	1783	benefit	benefit	NN	I-NP
O	1784	1786	to	to	TO	B-PP
O	1787	1790	the	the	DT	B-NP
O	1791	1792	7	7	CD	I-NP
O	1792	1793	%	%	NN	I-NP
O	1794	1796	to	to	TO	I-NP
O	1797	1798	8	8	CD	I-NP
O	1798	1799	%	%	NN	I-NP
O	1800	1802	of	of	IN	B-PP
B-Cancer	1803	1809	breast	breast	NN	B-NP
I-Cancer	1810	1816	cancer	cancer	NN	I-NP
O	1817	1825	patients	patient	NNS	I-NP
O	1826	1830	with	with	IN	B-PP
O	1831	1835	this	this	DT	B-NP
B-Organ	1836	1840	lung	lung	NN	I-NP
O	1841	1848	disease	disease	NN	I-NP
O	1848	1849	.	.	.	O

